DPDaily Peptide

LL-37 · DECODED

← Back to Decoded
GREY MARKETENDOGENOUS · ANTIMICROBIAL PEPTIDE

LL-37

Decoded · Grey Market · Human Cathelicidin Antimicrobial Peptide

The body's own front-line antimicrobial peptide. The injectable version is a different conversation. LL-37 is the only human cathelicidin, an antimicrobial peptide your skin, neutrophils, and epithelial cells produce as a first line of defense against bacteria, viruses, and fungi. Topical human data is real. Injectable LL-37 is a different question with essentially no human clinical trial evidence.

BY THE NUMBERS

37
AMINO ACIDS (L-L DILEUCINE N-TERMINUS + 37 RESIDUES)
1
HUMAN CATHELICIDIN · ONLY ONE EXISTS (hCAP18/LL-37)
0
REGISTERED INJECTABLE HUMAN INTERVENTIONAL TRIALS
2027
PCAC MEETING #2 SCHEDULED BEFORE FEB 2027 FOR 503A REVIEW

HOW IT WORKS

The only member of the cathelicidin family in humans. Disrupts microbial cell membranes via amphipathic helix insertion, its primary antimicrobial mechanism. Also modulates immune signaling through formyl peptide receptors and TLR pathways. Topical antimicrobial activity is well-characterized. Systemic mechanisms in humans are proposed based on in vitro work and have not been confirmed from human interventional data.

WHERE IT CAME FROM

LL-37 is the only human cathelicidin, a class of antimicrobial peptides produced by innate immune cells as a first-line defense against pathogens. The full name hCAP18/LL-37 reflects its structure: hCAP18 is the full 18-kDa precursor protein, and LL-37 is the active C-terminal fragment named for its starting dileucine and 37-residue length. It is produced by neutrophils (white blood cells that engulf bacteria), epithelial cells in the skin, lungs, and gut, and is secreted directly onto mucosal surfaces as an immediate antimicrobial barrier.

LL-37 kills bacteria, viruses, and fungi by disrupting their cell membranes, and it also modulates immune signaling, reducing excessive inflammation in some contexts while amplifying the response in others. Because it is endogenous and has clear antimicrobial function, researchers have investigated both topical applications (wound healing, skin infections, acne) and systemic applications (sepsis, respiratory infections). Topical human data exists. Injectable LL-37 has no completed human interventional trials, and the systemic immune modulation role of LL-37 at exogenous doses is not well characterized in humans.

THE STUDIES

2005–2020
Topical antimicrobial and wound healing studies: A series of studies examined topical application of LL-37 in wound healing and skin infection contexts. LL-37 demonstrated antimicrobial activity against a range of pathogens in clinical and ex vivo settings, and some small trials showed accelerated wound closure. The evidence is strongest for topical antimicrobial activity and weakest for systemic applications. These studies involve human tissue but most are not large randomized controlled trials.
Preclinical
Respiratory and systemic infection models: Preclinical research examined LL-37 in lung infection and sepsis models, showing that it can reduce bacterial load and modulate inflammatory signaling in animal experiments. Some researchers have also investigated vitamin D's role in upregulating endogenous LL-37 production as an indirect immunomodulatory strategy, which has more human evidence than direct LL-37 supplementation. The direct injectable application for respiratory or systemic use in humans has no controlled trial data.
None
Injectable systemic human interventional trials: There are no registered, completed human clinical trials testing injectable or systemic LL-37 for any indication. The topical data cannot be extrapolated to systemic use without direct evidence. Administering LL-37 by injection exposes the compound to the systemic circulation, where its immune-modulating properties could interact with existing inflammatory states or medications in ways that have not been characterized in humans.

WHAT THE STUDIES SHOW

ESTABLISHED

  • ▸Endogenous antimicrobial peptide in humans (confirmed biology)
  • ▸Membrane disruption mechanism against bacteria, viruses, fungi
  • ▸Topical antimicrobial activity in small human studies
  • ▸Expressed in skin, neutrophils, epithelial surfaces

PRECLINICAL (SYSTEMIC)

  • ▸Respiratory infection protection in animal models
  • ▸Sepsis inflammatory modulation in animal studies
  • ▸Immune signaling modulation (bidirectional: can amplify or reduce)
  • ▸Anti-biofilm activity in vitro

UNKNOWN (INJECTABLE)

  • ▸Systemic safety in humans at exogenous doses
  • ▸Whether injectable administration produces useful blood levels vs. clearance
  • ▸Risk of dysregulated immune activation at high doses
  • ▸Long-term consequences of chronic systemic supplementation

SIDE EFFECTS

TOPICAL (KNOWN)

  • ▸Local skin irritation at high concentrations
  • ▸Mild inflammation at application site
  • ▸Well-tolerated at concentrations used in clinical studies

INJECTABLE (UNKNOWN / THEORETICAL)

  • ▸Immune activation risk: LL-37 modulates inflammatory signaling bidirectionally
  • ▸No controlled systemic safety data exists
  • ▸Grey market supply: purity, sterility, and concentration unverified
  • ▸Potential interaction with existing inflammatory conditions or autoimmune disease

REGULATORY STATUS

FDA STATUS
Not approved · Category 2 removal · PCAC Meeting #2 before Feb 2027
PHASE
Topical human data · Injectable: no completed human trials
PROJECTED NDA
None · No active pharmaceutical development for systemic use

LL-37 (Cathelicidin) was on the FDA's Category 2 list, prohibiting 503A compounding. On April 15, 2026, the FDA removed LL-37 from that prohibition as part of a 12-compound review. The PCAC is scheduled to review LL-37 and four other compounds at a second meeting before February 2027 (exact date pending). This means LL-37 is not scheduled for the July 23–24 meeting. Its regulatory review comes later. The April 2026 removal does not authorize compounding. LL-37 is not on any approved 503A bulk substances list. All injectable use represents obtaining the compound through unregulated channels.

PROS & CONS

PROS

  • +Endogenous peptide: the body produces it, providing biological legitimacy
  • +Topical antimicrobial mechanism is well-characterized and functionally established
  • +Topical human studies show real antimicrobial activity
  • +Broad-spectrum activity against bacteria, viruses, and fungi
  • +No WADA ban as of current review

CONS

  • −Injectable systemic use has no human interventional trial data
  • −Immune modulation is bidirectional: can amplify or suppress depending on context
  • −Grey market injectable supply has no quality control
  • −No FDA approval, no regulated compounding pathway currently
  • −PCAC review scheduled for before February 2027. Resolution timeline is uncertain.
  • −Topical evidence does not automatically extend to systemic claims

DAILY PEPTIDE VERDICT

RANKING

Topically Real, Systemically Theoretical

LL-37 as an endogenous antimicrobial peptide is well-established biology. The topical human data is real, if limited in scale. The injectable grey market use is a different situation: no completed human trials, no characterized dose-response in humans, and an immune-modulating mechanism that works bidirectionally. The immune system doesn't always want amplification; LL-37's effects depend on context in ways that haven't been studied at exogenous injectable doses. The PCAC review before February 2027 will be the first formal assessment of whether evidence warrants 503A compounding eligibility. Until that process runs, and ideally until controlled injectable human data exists, the injectable form represents a significant evidential extrapolation beyond what the data supports.

Also in IMMUNE

// IMMUNE

Thymosin α-1

GREY MARKETPHASE 3+

Not FDA approved · Internationally approved as Zadaxin in 35+ countries

// IMMUNE

KPV

GREY MARKETPRECLINICAL

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. LL-37 does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.